Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see what effect the combination of lenvatinib plus
everolimus has in local and metastatic renal cell carcinoma to potentially make surgically
unresectable tumors resectable.